ICOS and cancer: The identification of a number of surface protein targets on the CNS-homing T cell population in this study, including CD161, AQP3, LTB, ICOS, and TNFRSF25 (Figures 7C–7E, 7G, and S6), suggests possible options for developing tailored depletion therapies with tri-specific antibodies or combinatorial antigen-sensing cells, as has recently emerged for cancer therapy.38